Nexalin Technology, Inc. (NXL) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Nexalin Technology, Inc. on May 6, 2025, covering events occurring on May 4 and May 5, 2025. The Company, an emerging growth company incorporated in Delaware, is reporting the entry into a material definitive agreement regarding a public offering of common stock.
Key Financial Metrics and Transaction Details
The filing details a public offering of common stock with the following terms:
- Shares Offered: 3,850,000 shares of Common Stock.
- Public Offering Price: $1.30 per share.
- Gross Proceeds: Approximately $5.005 million (calculated as 3,850,000 shares x $1.30).
- Underwriting Fees: 8.0% of gross proceeds plus reimbursement of up to $110,000 in expenses.
- Underwriter: Maxim Group LLC.
- Expected Closing Date: May 6, 2025.
The filing text does not provide specific values for the Company's historical revenue, profit, cash flow, margins, or existing debt levels. This report focuses solely on the capital raise transaction.
Material Changes and Outlook
The primary material change is the execution of an underwriting agreement to raise capital. The offering was priced on May 5, 2025, following the effectiveness of a Registration Statement on Form S-3 on April 29, 2025. Management commentary is limited to standard forward-looking statements cautioning that the offering may not close if customary conditions are not met.
Risks and Contingencies
- Closing Risk: The offering is subject to customary closing conditions; failure to satisfy these conditions could result in the offering not occurring.
- Forward-Looking Statements: Actual results may differ materially from projections due to various risks and uncertainties.
- Indemnification: The Company has agreed to indemnification obligations under the Underwriting Agreement.
Key Facts for Investor Verification
- Verify the final closing of the offering on or after May 6, 2025.
- Confirm the net proceeds received after deducting the 8.0% underwriting discount and the $110,000 expense reimbursement.
- Review the full Underwriting Agreement (Exhibit 10.1) for specific representations, warranties, and covenants.
- Monitor the press release (Exhibit 99.1) for any updates on the use of proceeds or changes to the offering terms.